@EllisLab_@UrologySBUR@sfanoslab@PCF_Science Yes, that is one of the findings. SF3B1 positive tumors exhibit gaining of NEPC features (Fig 3 of poster). SF3B induced splicing causes loss of full length as well as big size variants of AR whereas generates variants of MYC ( with oncogenes function).
Rush was honored to get a shout-out today from President Biden, who lauded the Medical Center’s success in having its staff vaccinated against #COVID19. More at https://t.co/RPt0GK3GYP
We are proud to announce that @RushUrology is now the Department of Urology at Rush University Medical Center and Rush Medical College. Follow us for the latest news and announcements during our transition from division to department. #RushUrology
@EllisLab_ @NarjustDumaMD I have Same experience moving from Minnesota to Chicago. The bitter part is kids getting crazy in tighter space , compared to previous 10, 000sq ft backyard in Minnesota.
@PCFnews@UrologySBUR@UMNCancer Exciting story from my lab. in MOLECULAR CANCER THERAPEUTICS
Anti-S100A4 antibody therapy is efficient in treating aggressive prostate cancer and reversing immunosuppression: Serum and biopsy S100A4 as clinical predictor https://t.co/egTthQgGMJ
Congratulations to SCI member Tanya Stoyanova on receiving the NIH/NCI R01/R37 MERIT Award for her project, titled: Elucidating the Role of Trop2 in Prostate Cancer. Her research will test the role of a cell surface receptor activation in aggressive #prostatecancer. @stoyanovalab
Recent Paper from our lab available online . Identitying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African … https://t.co/vAwisL8EiR
@charlesryanmd@sghmd@cancerassassin1@HalaBorno@chadknezel @WonKimMD Always had a passion for two jobs(1) a film maker (2) Scientist: following happened in my life:
- helped brother at his store ; - joined school theatre, -door-door sales person
- math tutor to elementary school, - science teacher high school;